The purpose of this study was to compare the accuracy of measurements obtained from the DexCom™ SEVEN® system with Yellow Springs Instrument (YSI) laboratory measurements of venous blood glucose.
Methods:
Seventy-two subjects with insulin-requiring diabetes, aged 18–71, were enrolled in a multicenter, prospective single-arm study. All participants wore the SEVEN continuous glucose monitoring (CGM) system for one, 7-day wear period. Calibration with capillary finger stick measurements was performed 2 hours after sensor insertion and once every 12 hours thereafter. A subset of subjects (28) wore two systems simultaneously to assess precision. All subjects participated in one, 10-hour in-clinic session on day 1, 4, or 7 of the study to compare CGM measurements against a laboratory method (YSI analyzer) using venous measurements taken once every 20 minutes. Carbohydrate consumption and insulin dosing were adjusted in order to obtain a broad range of glucose values.
Results:
Comparison of CGM measurements with the laboratory reference method (n = 2318) gave mean and median absolute relative differences (ARDs) of 16.7 and 13.2%, respectively. The percentage was 70.4% in the clinically accurate Clarke error grid A zone and 27.5% in the benign error B zone. Performance of the SEVEN system was consistent over time with mean and median ARD lowest on day 7 as compared to YSI (13.3 and 10.2%, respectively). Average sensor time lag was 5 minutes.
Conclusions:
Measurements of the DexCom SEVEN system were found to be consistent and accurate compared with venous measurements made using a laboratory reference method over 7 days of wear.
SkylerJS. The economic burden of diabetes and the benefits of improved glycemic control: the potential role of a continuous glucose monitoring system. Diabetes Technol Ther.2000;2Suppl. 1: S7–12.
2.
KlonoffDC. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care.2005;28 (5): 1231–9.
BaileyTZisserHGargS. Reduction in reduction in hemoglobin A1c with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther.2007;9 (3): 203–9.
5.
GargSJovanovicL. Relationship of fasting and hourly blood glucose levels to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Diabetes Care.2005;29 (12): 2644–9.
6.
ChaseHPKimLMOwenSLMacKenzieTAKlingensmithGJMurtfeldtRGargSK. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics.2001;107 (2): 222–6.
7.
ChaseHPRobertsMDWightmanCKlingensmithGGargSKVan WyheMDesaiSHarperWLopatinMBartkowiakMTamadaJEastmanRC. Use of the GlucoWatch Biographer in children with type 1 diabetes. Pediatrics.2003;111 (4 Pt 1): 790–4.
8.
LudvigssonJHanasR. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics.2003;111 (5 Pt 1): 933–8.
9.
TanenbergRBodeBLaneWLevetanCMestmanJHarmelAPTobianJGrossTMastrototaroJ. Use of the continuous glucose monitoring system to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clin Proc.2004;79 (12): 1521–6.
10.
BodeBWGrossTMThorntonKRMastrototaroJJ. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Res Clin Pract.1999;46 (3): 183–90.
11.
SchiaffiniRCiampaliniPFierabracciASperaSBorrelliPBottazzoGFCrinoA. The Continuous Glucose Monitoring System (CGMS) in type 1 diabetic children is the way to reduce hypoglycemic risk. Diabetes Metab Res Rev.2002;18 (4): 324–9.
12.
Schaepelynck-BelicarPVaguePSimoninGLassmann-VagueV. Improved metabolic control in diabetic adolescents using the continuous glucose monitoring system (CGMS). Diabetes Metab.2003;29 (6): 608–12.
13.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, TamborlaneWVBeckRWBodeBWBuckinghamBChaseHPClemonsRFiallo-ScharerRFoxLAGilliamLKHirschIBHuangESKollmanCKowalskiAJLaffelLLawrenceJMLeeJMaurasNO'GradyMRuedyKJTanseyMTsalikianEWeinzimerSWilsonDMWolpertHWysockiTXingD. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med.2008;359 (14): 1464–76.
14.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med.1993;329 (14): 977–86.
15.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet.1998;352 (9131): 854–65.
16.
Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA.2003;290 (16): 2159–67.
17.
NathanDMClearyPABacklundJYGenuthSMLachinJMOrchardTJRaskinPZinmanB; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med.2005;353 (25): 2643–53.
18.
The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes.1995;44 (8): 968–83.
19.
HirschIBBrownleeM. Should minimal blood glucose variability become the gold standard of glycemic control?J Diabetes Complications.2005;19 (3): 178–81.
20.
MonnierLMasEGinetCMichelFVillonLCristolJColetteC. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA.2006;295 (14): 1681–7.
21.
BrownleeMHirschIB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA.2006;295 (14): 1707–8.
22.
The Diabetes Research in Children Network (DirecNet) Study Group. The accuracy of the CGMS in children with type 1 diabetes: results of the Diabetes Research in Children Network (DirecNet) accuracy study. Diabetes Technol Ther.2003;5 (5): 781–9.
23.
ChiaCWSaudekCD. Glucose sensors: toward closed loop insulin delivery. Endocrinol Metab Clin North Am.2004;33 (1): 175–95, xi.
U.S. Food and Drug Administration. Summary of safety and effectiveness data: Medtronic Guardian RT [article online], 2006 [cited 2008 Sep 4]. Available from: http://www.fda.gov/cdrh/PDF/p980022s011b.pdf.
26.
U.S. Food and Drug Administration. Summary of safety and effectiveness data: DexCom STS continuous glucose monitoring system [article online], 2007[cited 2008 Sep 4]. Available from: http://www.fda.gov/cdrh/pdf5/p050012b.pdf.
27.
U.S. Food and Drug Administration. Summary of safety and effectiveness data: Abbott Freestyle Navigator [article online], 2008 [cited 2008 Sep 4]. Available from: http://www.fda.gov/cdrh/pdf5/p050020b.pdf.
28.
GargSZisserHSchwartzSBaileyTKaplanREllisSJovanovicL. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care.2006;29 (1): 44–50.
29.
DemingWE. Statistical adjustment of data. New York: Dover; 1964.
30.
BraukerJKamathALiYZisserHSchwartzSRatnerRWiseJBaileyTS. Time lag of a seven-day transcutaneous continuous glucose sensor compared to YSI blood glucose values [poster]. The 67th Scientific Sessions of the American Diabetes Association, Chicago, IL; 2007.
31.
CoxDJClarkeWLGonder-FrederickLPohlSHooverCSnyderAZimbelmanLCarterWRBobbittSPennebakerJ. Accuracy of perceiving blood glucose in IDDM. Diabetes Care.1985;8 (6): 529–36.
32.
ClarkeWLCoxDGonder-FrederickLACarterWPohlSL. Evaluating clinical accuracy of systems for self-monitoring of blood glucose. Diabetes Care.1987;10 (5): 622–8.
33.
KovatchevBPGonder-FrederickLACoxDJClarkeWL. Evaluating the accuracy of continuous glucose-monitoring sensors: continuous glucose-error grid analysis illustrated by TheraSense Freestyle Navigator data. Diabetes Care.2004;27 (8): 1922–8.
34.
WeinsteinRSchwartzSLBrazgRLBuglerJRPeyserTAMcGarraughGV. Accuracy of the 5-Day Freestyle Navigator Continuous Glucose Monitoring System: comparison with frequent laboratory reference measurements. Diabetes Care.2007;30 (5): 1125–30.
35.
GargSKSmithJBeatsonCLopez-BacaBVoelmleMGottliebPA. Comparison of accuracy and safety of the SEVEN and the Navigator continuous glucose monitoring systems. Diabetes Technol Ther.2009;11 (2): 65–72.
36.
BaileyTZisserHChangALiDJonesKGargSK. Performance of the DexCom SEVEN continuous glucose monitoring system with manual entry of calibration blood glucose values [abstract 19999-PO]. Diabetes.2008;57 (Suppl 1): A552.
